ClinicalTrials.gg
CompletedNCT05767021LUCENT-URGEUpdated Jun 10, 2026Results posted

A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis

A Phase 3 interventional study of Mirikizumab and Mirikizumab in Ulcerative Colitis and Ulcerative Colitis Chronic, sponsored by Eli Lilly and Company. Completed at 120 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-10.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
172
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing mirikizumab in Colitis, Ulcerative — 4 open to participants now, 5 under way, 2 of them phase 3. mirikizumab · Colitis, Ulcerative.

Enrollment
7th of 13
172 · median 172
Started
2023
with 1 other
Phase 3
7 of 13
1 open now
Registered
8th of 13
by date
Lead sponsor
9 of 13
Eli Lilly and Company

Among the 13 studies testing mirikizumab in Colitis, Ulcerative, this one is the 7th largest by enrollment, is one of 2 that started in 2023, is one of 7 in phase 3, and was the 8th registered.

Colitis, Ulcerative

1,856 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

4 of the 13 studies testing mirikizumab in Colitis, Ulcerative are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About mirikizumab

mirikizumab: first FDA approval 2023 (OMVOH), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 306 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 135 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing mirikizumab in Colitis, Ulcerative, or all of them as a file.
02

Study summary

A study to investigate bowel urgency in adults with moderately to severely active ulcerative colitis (UC) treated with mirikizumab. The study will have 4 periods and will last for 36 weeks.

03

Conditions studied

  • Ulcerative Colitis
  • Ulcerative Colitis Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have an established diagnosis of UC for ≥3 months
  • Have confirmed diagnosis of moderately for severely active UC
  • Have current bowel urgency
  • Have demonstrated an inadequate response to, a loss of response to, or an intolerance to conventional or to biologic/Janus Kinase (JAK) inhibitor/sphingosine-1-phosphate (S1P) receptor modulator therapy for UC.

Exclusion criteria

Exclusion Criteria:

  • Have Crohn's disease (CD)
  • Have inflammatory bowel disease-unclassified, formerly known as indeterminate colitis, or
  • Have ulcerative proctitis, disease limited to the rectum, that is, distal to the recto-sigmoid junction, which lies approximately 10 to 15 centimeter (cm) from anal verge.
  • Have an inherited immunodeficiency syndrome or a monogenic cause of UC-like colonic inflammation
  • Have any history or current evidence of cancer of the gastrointestinal tract
  • Have active tuberculosis
  • Have infection.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
172 participants (actual)

Study arms

  • Experimental
    300 mg Mirikizumab

    Participants received 300 milligram (mg) mirikizumab every 4 weeks (Q4W) at week 0, 4, and 8 administered intravenously (IV).

    Drug: Mirikizumab

Interventions

  • Administered IV

    Also known as: LY3074828

  • Administered Subcutaneously (SC)

    Also known as: LY3074828

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Bowel Urgency Severity Urgency Numeric Rating Scale (UNRS)

    The UNRS is a single participant reported item that measures the severity for the urgency (sudden or immediate need) to have a bowel movement in the past 24 hours using an 11-point NRS ranging from 0 (no urgency) to 10 (worst possible urgency). Higher scores indicate more severe urgency. Baseline Observation Carried Forward (BOCF) endpoint was defined as the baseline value for participants discontinued during acute phase and defined as the last non-missing observation in the treatment phase for all other randomized participants.

    Time frame: Baseline, Week 12

Secondary outcomes

  1. Change From Baseline in Bowel Urgency Frequency (BUF)

    BUF is participant reported single item measure of the number of urgent bowel movements reported in the past 24 hours.

    Time frame: Baseline, Week 12

  2. Percentage of Participants Achieving Clinically Meaningful Improvement in BUF

    This outcome measures the percentage of participants who experience a clinically meaningful reduction in the frequency of bowel urgency episodes from baseline to the 12 week treatment period. Results for this outcome will be reported during final results posting.

    Time frame: Baseline to Week 12

  3. Percentage of Participants With Stool Deferral Time (SDT) Intervals at Week 12

    The SDT is a participant-reported single item measure of the average duration a patient could delay defecation in the past 24 hours. The shortest weekly SDT is used for analysis of SDT in minutes by taking the shortest response (i.e. minimum value) available over the past 7 days, where no urgency is treated as the largest value. The SDT categories were:\<1 min, ≥1 min to \<2 min, ≥2 min to \<5 min, ≥5 min to \<15 min, and ≥15 min or no urgency. No urgency indicates participant's selected "Did not feel urge to have a bowel movement in the past 24 hours" for all available days in 7-day period.

    Time frame: Week 12

  4. Percentage of Participants Achieving Clinically Meaningful Improvement of SDT

    This outcome measures the percentage of participants who demonstrate a clinically meaningful improvement in SDT. Results for this outcome will be reported during final results posting.

    Time frame: Week 12

  5. Percentage of Participants Achieving Both Clinical Remission, Based on the Modified Mayo Score (MMS) and a Rounded Urgency Numeric Rating Scale (UNRS) Score of ≤1

    Clinical remission based on MMS is defined as Stool Frequency (SF) sub score (range 0-3, higher is worse) = 0, or SF = 1 with a ≥1- point decrease from baseline, and 1. Rectal Bleeding (RB) sub score (range 0-3, higher is worse) = 0, and 2. Endoscopic sub score (ES) (range 0-3, higher is worse) = 0 or 1 (excluding friability). UNRS measures bowel urgency severity (range 0 to 10; Higher scores indicate more severe urgency) This outcome assesses the proportion of participants who achieved both a clinical response, as defined by an MMS, and an improvement of ≥3 points from baseline in a UNRS score at Week 12.

    Time frame: Week 12

  6. Percentage of Participants Achieving Both Clinical Response, Based on the Modified Mayo Score (MMS) and a Rounded Urgency Numeric Rating Scale (UNRS) Score ≥3 Points of Improvement From Baseline

    Clinical response based on MMS is defined as: 1. A change in the MMS of ≤ -2 points and ≤ -30% change from baseline, and 2. A change of ≤-1 point in the RB subscore (range 0-3, higher is worse) from baseline or a RB score of 0 or 1. UNRS measures bowel urgency severity (range 0 to 10; Higher scores indicate more severe urgency) This outcome measures the percentage of participants achieving both, clinical response, based on the MMS, and a UNRS score of ≥3 points of improvement from baseline at 12 weeks.

    Time frame: Week 12

  7. Pairwise Correlations Between the Urgency Numeric Rating Scale (UNRS), Baseline in Bowel Urgency Frequency (BUF), Stool Deferral Time (SDT) and Absorbent Product Use (APU) Measures

    UNRS measures bowel urgency severity (range 0 to 10; Higher scores indicate more severe urgency). BUF measures the number of urgent bowel movements reported in the past 24 hours. SDT measures the average duration a patient could delay defecation in the past 24 hours. APU is a single item to assess participant's need to wear an adult diaper, pad or protection because of bowel urgency. This outcome evaluates the pairwise correlations among four bowel urgency-related measures above.

    Time frame: Baseline to Week 12

  8. Pairwise Correlations Between Change From Baseline in Urgency Numeric Rating Scale (UNRS), Baseline in Bowel Urgency Frequency (BUF), Stool Deferral Time (SDT) and Absorbent Product Use (APU) Measures

    UNRS measures bowel urgency severity (range 0 to 10; Higher scores indicate more severe urgency). BUF measures the number of urgent bowel movements reported in the past 24 hours. SDT measures the average duration a patient could delay defecation in the past 24 hours. APU is a single item to assess participant's need to wear an adult diaper, pad or protection because of bowel urgency. This outcome evaluates the pairwise correlations between the change in correlations among four bowel urgency-related measures above.

    Time frame: Baseline, Week 12

  9. Correlation Between Urgency Numeric Rating Scale (UNRS), Baseline in Bowel Urgency Frequency (BUF),Stool Deferral Time (SDT) and Absorbent Product Use (APU) Measures,With Quality of Life (QoL)/Functional Outcome Measures and UC Symptom Measures

    This outcome evaluates correlations between UNRS, BUF, SDT, APU, and patient-reported outcomes (PROs) related to quality of life (QoL), functional outcomes, and UC symptoms. QoL is assessed using the Inflammatory Bowel Disease Questionnaire (IBDQ), a 32-item patient-completed tool with four domains: bowel (score range 10-70), systemic (5-35), emotional (12-84), and social (5-35). Each item is rated on a 7-point Likert scale (1 = very severe problem,7 = not a problem at all); The total IBDQ score is calculated by summing the scores from all four domains and total score range is 32-224 (Higher = better QoL). Functional outcomes measures: Work Productivity and Activity Impairment (WPAI) questionnaire (four scores derived: absenteeism, presenteeism, productivity loss, activity impairment; each score 0-100%, higher = greater impairment) and Generalized Anxiety Disorder-7 (GAD-7; total score range 0-21, higher = more severe anxiety)... (Continued below due to character constraint)

    Time frame: Baseline to Week 12 UC symptom measures:Patient Global Rating of Severity (PGR-S)(1-6),Patient Global Impression of Change (PGI-C)(1-7),Mayo SF/RB (0-3),Abdominal pain/fatigue NRS (0-10),nocturnal stool frequency;higher=worse severity for all measures.

  10. Correlation Between Change From Baseline in Urgency Numeric Rating Scale (UNRS), Baseline in Bowel Urgency Frequency (BUF), Stool Deferral Time (SDT) and Absorbent Product Use (APU) Measures, With QoL/Functional Outcome Measures and UC Symptom Measures

    This outcome evaluates correlations between change from baseline in UNRS, BUF, SDT, APU, and PROs related to quality of life (QoL), functional outcomes, and UC symptoms. QoL is assessed using the Inflammatory Bowel Disease Questionnaire (IBDQ), a 32-item patient-completed tool with four domains: bowel (score range 10-70), systemic (5-35), emotional (12-84), and social (5-35). Each item is rated on a 7-point Likert scale (1 = very severe problem, 7 = not a problem at all); The total IBDQ score is calculated by summing the scores from all four domains and total score range is 32-224 (Higher = better QoL). Functional outcomes measures: Work Productivity and Activity Impairment (WPAI) questionnaire (four scores derived: absenteeism, presenteeism, productivity loss, activity impairment; each score 0-100%, higher = greater impairment) and Generalized Anxiety Disorder-7 (GAD-7;total score range 0-21, higher = more severe anxiety)... (Continued below due to character constraint)

    Time frame: Baseline, Week 12 UC symptom measures:Patient Global Rating of Severity (PGR-S)(1-6),Patient Global Impression of Change (PGI-C)(1-7),Mayo SF/RB (0-3),Abdominal pain/fatigue NRS (0-10),nocturnal stool frequency; higher=worse severity for all measures.

07

Results

Posted Sep 30, 2025

Participant flow

Participant flow — Overall Study
Milestone300 mg Mirikizumab
Started172
Received at least one dose of study drug172
Completed155
Not completed17
Withdrew: Adverse event2
Withdrew: Protocol deviation1
Withdrew: Withdrawal by subject1
Withdrew: Physician decision1
Withdrew: Lack of efficacy11
Withdrew: Assigned treatment by mistake1

Outcome measures

PrimaryChange From Baseline in Bowel Urgency Severity Urgency Numeric Rating Scale (UNRS)

The UNRS is a single participant reported item that measures the severity for the urgency (sudden or immediate need) to have a bowel movement in the past 24 hours using an 11-point NRS ranging from 0 (no urgency) to 10 (worst possible urgency). Higher scores indicate more severe urgency. Baseline Observation Carried Forward (BOCF) endpoint was defined as the baseline value for participants discontinued during acute phase and defined as the last non-missing observation in the treatment phase for all other randomized participants.

Time frame:
Baseline, Week 12
Reported as:
Mean · score on a scale
Change From Baseline in Bowel Urgency Severity Urgency Numeric Rating Scale (UNRS)
score on a scale300 mg Mirikizumab
Change From Baseline in Bowel Urgency Severity Urgency Numeric Rating Scale (UNRS)-3.25 (-3.63 to -2.87)
SecondaryChange From Baseline in Bowel Urgency Frequency (BUF)

BUF is participant reported single item measure of the number of urgent bowel movements reported in the past 24 hours.

Time frame:
Baseline, Week 12
Reported as:
Mean · counts of urgent bowel movements/day
Change From Baseline in Bowel Urgency Frequency (BUF)
counts of urgent bowel movements/day300 mg Mirikizumab
Change From Baseline in Bowel Urgency Frequency (BUF)-3.83 (-4.33 to -3.33)
SecondaryPercentage of Participants Achieving Clinically Meaningful Improvement in BUF

This outcome measures the percentage of participants who experience a clinically meaningful reduction in the frequency of bowel urgency episodes from baseline to the 12 week treatment period. Results for this outcome will be reported during final results posting.

Time frame:
Baseline to Week 12

Results for this outcome have not been posted.

SecondaryPercentage of Participants With Stool Deferral Time (SDT) Intervals at Week 12

The SDT is a participant-reported single item measure of the average duration a patient could delay defecation in the past 24 hours. The shortest weekly SDT is used for analysis of SDT in minutes by taking the shortest response (i.e. minimum value) available over the past 7 days, where no urgency is treated as the largest value. The SDT categories were:\<1 min, ≥1 min to \<2 min, ≥2 min to \<5 min, ≥5 min to \<15 min, and ≥15 min or no urgency. No urgency indicates participant's selected "Did not feel urge to have a bowel movement in the past 24 hours" for all available days in 7-day period.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Stool Deferral Time (SDT) Intervals at Week 12
percentage of participants300 mg Mirikizumab
<1 min8.7
>=1 to <2 min21.5
>=2 to <5 min30.2
>=5 to <15 min23.8
>=15 min or no urgency15.7
SecondaryPercentage of Participants Achieving Clinically Meaningful Improvement of SDT

This outcome measures the percentage of participants who demonstrate a clinically meaningful improvement in SDT. Results for this outcome will be reported during final results posting.

Time frame:
Week 12

Results for this outcome have not been posted.

SecondaryPercentage of Participants Achieving Both Clinical Remission, Based on the Modified Mayo Score (MMS) and a Rounded Urgency Numeric Rating Scale (UNRS) Score of ≤1

Clinical remission based on MMS is defined as Stool Frequency (SF) sub score (range 0-3, higher is worse) = 0, or SF = 1 with a ≥1- point decrease from baseline, and 1. Rectal Bleeding (RB) sub score (range 0-3, higher is worse) = 0, and 2. Endoscopic sub score (ES) (range 0-3, higher is worse) = 0 or 1 (excluding friability). UNRS measures bowel urgency severity (range 0 to 10; Higher scores indicate more severe urgency) This outcome assesses the proportion of participants who achieved both a clinical response, as defined by an MMS, and an improvement of ≥3 points from baseline in a UNRS score at Week 12.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Both Clinical Remission, Based on the Modified Mayo Score (MMS) and a Rounded Urgency Numeric Rating Scale (UNRS) Score of ≤1
percentage of participants300 mg Mirikizumab
Percentage of Participants Achieving Both Clinical Remission, Based on the Modified Mayo Score (MMS) and a Rounded Urgency Numeric Rating Scale (UNRS) Score of ≤15.23
SecondaryPercentage of Participants Achieving Both Clinical Response, Based on the Modified Mayo Score (MMS) and a Rounded Urgency Numeric Rating Scale (UNRS) Score ≥3 Points of Improvement From Baseline

Clinical response based on MMS is defined as: 1. A change in the MMS of ≤ -2 points and ≤ -30% change from baseline, and 2. A change of ≤-1 point in the RB subscore (range 0-3, higher is worse) from baseline or a RB score of 0 or 1. UNRS measures bowel urgency severity (range 0 to 10; Higher scores indicate more severe urgency) This outcome measures the percentage of participants achieving both, clinical response, based on the MMS, and a UNRS score of ≥3 points of improvement from baseline at 12 weeks.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Both Clinical Response, Based on the Modified Mayo Score (MMS) and a Rounded Urgency Numeric Rating Scale (UNRS) Score ≥3 Points of Improvement From Baseline
percentage of participants300 mg Mirikizumab
Percentage of Participants Achieving Both Clinical Response, Based on the Modified Mayo Score (MMS) and a Rounded Urgency Numeric Rating Scale (UNRS) Score ≥3 Points of Improvement From Baseline44.19
SecondaryPairwise Correlations Between the Urgency Numeric Rating Scale (UNRS), Baseline in Bowel Urgency Frequency (BUF), Stool Deferral Time (SDT) and Absorbent Product Use (APU) Measures

UNRS measures bowel urgency severity (range 0 to 10; Higher scores indicate more severe urgency). BUF measures the number of urgent bowel movements reported in the past 24 hours. SDT measures the average duration a patient could delay defecation in the past 24 hours. APU is a single item to assess participant's need to wear an adult diaper, pad or protection because of bowel urgency. This outcome evaluates the pairwise correlations among four bowel urgency-related measures above.

Time frame:
Baseline to Week 12
Reported as:
Number · Spearman Correlation Coefficient
Pairwise Correlations Between the Urgency Numeric Rating Scale (UNRS), Baseline in Bowel Urgency Frequency (BUF), Stool Deferral Time (SDT) and Absorbent Product Use (APU) Measures
Spearman Correlation Coefficient300 mg Mirikizumab
Correlation between UNRS and BUF0.68 (0.58 to 0.75)
Correlation between UNRS and SDT-0.50 (-0.61 to -0.37)
Correlation between UNRS and APU0.37 (0.22 to 0.50)
Correlation between BUF and SDT-0.47 (-0.58 to -0.34)
Correlation between BUF and APU0.45 (0.31 to 0.56)
Correlation between SDT and APU-0.37 (-0.49 to -0.22)
SecondaryPairwise Correlations Between Change From Baseline in Urgency Numeric Rating Scale (UNRS), Baseline in Bowel Urgency Frequency (BUF), Stool Deferral Time (SDT) and Absorbent Product Use (APU) Measures

UNRS measures bowel urgency severity (range 0 to 10; Higher scores indicate more severe urgency). BUF measures the number of urgent bowel movements reported in the past 24 hours. SDT measures the average duration a patient could delay defecation in the past 24 hours. APU is a single item to assess participant's need to wear an adult diaper, pad or protection because of bowel urgency. This outcome evaluates the pairwise correlations between the change in correlations among four bowel urgency-related measures above.

Time frame:
Baseline, Week 12
Reported as:
Number · Spearman Correlation Coefficient
Pairwise Correlations Between Change From Baseline in Urgency Numeric Rating Scale (UNRS), Baseline in Bowel Urgency Frequency (BUF), Stool Deferral Time (SDT) and Absorbent Product Use (APU) Measures
Spearman Correlation Coefficient300 mg Mirikizumab
Correlation between UNRS and BUF0.49 (0.36 to 0.60)
Correlation between UNRS and SDT-0.48 (-0.59 to -0.35)
Correlation between UNRS and APU0.17 (0.01 to 0.32)
Correlation between BUF and SDT-0.27 (-0.41 to -0.12)
Correlation between BUF and APU0.16 (0.00 to 0.31)
Correlation between SDT and APU0.07 (-0.09 to 0.23)
SecondaryCorrelation Between Urgency Numeric Rating Scale (UNRS), Baseline in Bowel Urgency Frequency (BUF),Stool Deferral Time (SDT) and Absorbent Product Use (APU) Measures,With Quality of Life (QoL)/Functional Outcome Measures and UC Symptom Measures

This outcome evaluates correlations between UNRS, BUF, SDT, APU, and patient-reported outcomes (PROs) related to quality of life (QoL), functional outcomes, and UC symptoms. QoL is assessed using the Inflammatory Bowel Disease Questionnaire (IBDQ), a 32-item patient-completed tool with four domains: bowel (score range 10-70), systemic (5-35), emotional (12-84), and social (5-35). Each item is rated on a 7-point Likert scale (1 = very severe problem,7 = not a problem at all); The total IBDQ score is calculated by summing the scores from all four domains and total score range is 32-224 (Higher = better QoL). Functional outcomes measures: Work Productivity and Activity Impairment (WPAI) questionnaire (four scores derived: absenteeism, presenteeism, productivity loss, activity impairment; each score 0-100%, higher = greater impairment) and Generalized Anxiety Disorder-7 (GAD-7; total score range 0-21, higher = more severe anxiety)... (Continued below due to character constraint)

Time frame:
Baseline to Week 12 UC symptom measures:Patient Global Rating of Severity (PGR-S)(1-6),Patient Global Impression of Change (PGI-C)(1-7),Mayo SF/RB (0-3),Abdominal pain/fatigue NRS (0-10),nocturnal stool frequency;higher=worse severity for all measures.
Reported as:
Number · Spearman Correlation Coefficient
Correlation Between Urgency Numeric Rating Scale (UNRS), Baseline in Bowel Urgency Frequency (BUF),Stool Deferral Time (SDT) and Absorbent Product Use (APU) Measures,With Quality of Life (QoL)/Functional Outcome Measures and UC Symptom Measures
Spearman Correlation Coefficient300 mg Mirikizumab
UNRS-IBDQ: IBDQ Total score-0.55 (-0.65 to -0.42)
UNRS-IBDQ: Bowel symptoms-0.48 (-0.60 to -0.35)
UNRS-IBDQ: Systemic symptoms-0.50 (-0.61 to -0.37)
UNRS-IBDQ: Emotional function-0.51 (-0.62 to -0.38)
UNRS-IBDQ: Social function-0.49 (-0.61 to -0.36)
UNRS-WPAI: Work Productivity Loss Score0.40 (0.21 to 0.55)
UNRS-WPAI: Absenteeism Score0.28 (0.10 to 0.45)
UNRS-WPAI: Presenteeism Score0.39 (0.21 to 0.55)
UNRS-WPAI: Activity Impairment Score0.54 (0.41 to 0.64)
UNRS-Generalize Anxiety Disorder-7 Score0.36 (0.21 to 0.49)
BUF-IBDQ: IBDQ Total score-0.60 (-0.69 to -0.48)
BUF-IBDQ: Bowel symptoms-0.57 (-0.67 to -0.45)
BUF-IBDQ: Systemic symptoms-0.57 (-0.67 to -0.45)
BUF-IBDQ: Emotional function-0.51 (-0.62 to -0.37)
BUF-IBDQ: Social function-0.58 (-0.68 to -0.46)
BUF-WPAI: Work Productivity Loss Score0.50 (0.33 to 0.63)
BUF-WPAI: Absenteeism Score0.27 (0.08 to 0.43)
BUF-WPAI: Presenteeism Score0.50 (0.33 to 0.63)
BUF-WPAI: Activity Impairment Score0.60 (0.48 to 0.69)
BUF-Generalize Anxiety Disorder-7 Score0.35 (0.20 to 0.48)
SDT-IBDQ: IBDQ Total score0.37 (0.22 to 0.50)
SDT-IBDQ: Bowel symptoms0.36 (0.21 to 0.49)
SDT-IBDQ: Systemic symptoms0.34 (0.19 to 0.48)
SDT-IBDQ: Emotional function0.32 (0.16 to 0.46)
SDT-IBDQ: Social function0.34 (0.19 to 0.48)
SDT-WPAI: UC Work Productivity Loss Score-0.29 (-0.46 to -0.10)
SDT-WPAI: UC Absenteeism Score-0.18 (-0.36 to 0.01)
SDT-WPAI: UC Presenteeism Score-0.30 (-0.47 to -0.11)
SDT-WPAI: UC Activity Impairment Score-0.29 (-0.43 to -0.14)
SDT-Generalize Anxiety Disorder-7 Score-0.26 (-0.40 to -0.11)
SDT-APU for BU-0.37 (-0.49 to -0.22)
APU-IBDQ: IBDQ Total score-0.51 (-0.62 to -0.38)
APU-IBDQ: Bowel symptoms-0.46 (-0.58 to -0.32)
APU-IBDQ: Systemic symptoms-0.43 (-0.56 to -0.29)
APU-IBDQ: Emotional function-0.45 (-0.57 to -0.30)
APU-IBDQ: Social function-0.54 (-0.64 to -0.41)
APU-WPAI: Work Productivity Loss Score0.43 (0.25 to 0.58)
APU-WPAI: Absenteeism Score0.22 (0.03 to 0.40)
APU-WPAI: Presenteeism Score0.41 (0.22 to 0.56)
APU-WPAI: Activity Impairment Score0.48 (0.34 to 0.59)
APU-Generalize Anxiety Disorder-7 Score0.25 (0.09 to 0.39)
UNRS: PGR-S0.64 (0.54 to 0.72)
UNRS: PGI-C0.45 (0.31 to 0.56)
UNRS: Mayo SF0.35 (0.20 to 0.48)
UNRS: Mayo RB0.21 (0.05 to 0.35)
UNRS: Abdominal Pain NRS0.62 (0.51 to 0.70)
UNRS: Fatigue NRS0.58 (0.47 to 0.67)
UNRS: Nocturnal Stool0.49 (0.36 to 0.59)
BUF: PGR-S0.65 (0.56 to 0.73)
BUF: PGI-C0.45 (0.31 to 0.56)
BUF: Mayo SF0.53 (0.40 to 0.63)
BUF: Mayo RB0.22 (0.07 to 0.36)
BUF: Abdominal Pain NRS0.55 (0.43 to 0.65)
BUF: Fatigue NRS0.49 (0.36 to 0.60)
BUF: Nocturnal Stool0.62 (0.51 to 0.70)
SDT: PGR-S-0.44 (-0.56 to -0.31)
SDT:Absolute SF-0.30 (-0.43 to -0.15)
SDT: Mayo SF-0.28 (-0.41 to -0.13)
SDT: Mayo RB-0.22 (-0.36 to -0.07)
SDT: Abdominal Pain NRS-0.44 (-0.55 to -0.30)
SDT: Fatigue NRS-0.30 (-0.43 to -0.15)
SDT: Nocturnal Stool-0.33 (-0.46 to -0.19)
SDT: PGI-C-0.29 (-0.43 to -0.14)
APU: PGR-S0.39 (0.25 to 0.52)
APU: PGI-C0.35 (0.20 to 0.48)
APU: Mayo SF0.44 (0.30 to 0.55)
APU: Mayo RB0.22 (0.06 to 0.36)
APU: Abdominal Pain NRS0.23 (0.07 to 0.37)
APU: Fatigue NRS0.29 (0.14 to 0.43)
APU: Nocturnal Stool0.50 (0.37 to 0.61)
SecondaryCorrelation Between Change From Baseline in Urgency Numeric Rating Scale (UNRS), Baseline in Bowel Urgency Frequency (BUF), Stool Deferral Time (SDT) and Absorbent Product Use (APU) Measures, With QoL/Functional Outcome Measures and UC Symptom Measures

This outcome evaluates correlations between change from baseline in UNRS, BUF, SDT, APU, and PROs related to quality of life (QoL), functional outcomes, and UC symptoms. QoL is assessed using the Inflammatory Bowel Disease Questionnaire (IBDQ), a 32-item patient-completed tool with four domains: bowel (score range 10-70), systemic (5-35), emotional (12-84), and social (5-35). Each item is rated on a 7-point Likert scale (1 = very severe problem, 7 = not a problem at all); The total IBDQ score is calculated by summing the scores from all four domains and total score range is 32-224 (Higher = better QoL). Functional outcomes measures: Work Productivity and Activity Impairment (WPAI) questionnaire (four scores derived: absenteeism, presenteeism, productivity loss, activity impairment; each score 0-100%, higher = greater impairment) and Generalized Anxiety Disorder-7 (GAD-7;total score range 0-21, higher = more severe anxiety)... (Continued below due to character constraint)

Time frame:
Baseline, Week 12 UC symptom measures:Patient Global Rating of Severity (PGR-S)(1-6),Patient Global Impression of Change (PGI-C)(1-7),Mayo SF/RB (0-3),Abdominal pain/fatigue NRS (0-10),nocturnal stool frequency; higher=worse severity for all measures.
Reported as:
Number · Spearman Correlation Coefficient
Correlation Between Change From Baseline in Urgency Numeric Rating Scale (UNRS), Baseline in Bowel Urgency Frequency (BUF), Stool Deferral Time (SDT) and Absorbent Product Use (APU) Measures, With QoL/Functional Outcome Measures and UC Symptom Measures
Spearman Correlation Coefficient300 mg Mirikizumab
UNRS-IBDQ: IBDQ Total score-0.546 (-0.654 to -0.414)
UNRS-IBDQ: Bowel symptoms-0.522 (-0.634 to -0.385)
UNRS-IBDQ: Systemic symptoms-0.473 (-0.594 to -0.329)
UNRS-IBDQ: Emotional function-0.485 (-0.604 to -0.342)
UNRS-IBDQ: Social function-0.454 (-0.578 to -0.307)
UNRS-WPAI: Work Productivity Loss Score0.488 (0.286 to 0.645)
UNRS-WPAI: Absenteeism Score0.092 (-0.108 to 0.285)
UNRS-WPAI: Presenteeism Score0.509 (0.312 to 0.661)
UNRS-WPAI: Activity Impairment Score0.451 (0.309 to 0.571)
UNRS-Generalize Anxiety Disorder-7 Score0.179 (0.015 to 0.331)
BUF-IBDQ: IBDQ Total score-0.399 (-0.532 to -0.245)
BUF-IBDQ: Bowel symptoms-0.380 (-0.515 to -0.223)
BUF-IBDQ: Systemic symptoms-0.353 (-0.492 to -0.194)
BUF-IBDQ: Emotional function-0.278 (-0.427 to -0.113)
BUF-IBDQ: Social function-0.378 (-0.514 to -0.222)
BUF-WPAI: Work Productivity Loss Score0.275 (0.044 to 0.475)
BUF-WPAI: Absenteeism Score0.150 (-0.051 to 0.338)
BUF-WPAI: Presenteeism Score0.275 (0.045 to 0.475)
BUF-WPAI: Activity Impairment Score0.356 (0.203 to 0.489)
BUF-WPAI: Generalize Anxiety Disorder-7 Score0.130 (-0.034 to 0.287)
SDT-IBDQ: IBDQ Total score0.22 (0.05 to 0.38)
SDT-IBDQ: Bowel symptoms0.26 (0.10 to 0.41)
SDT-IBDQ: Systemic symptoms0.18 (0.01 to 0.34)
SDT-IBDQ: Emotional function0.16 (-0.01 to 0.32)
SDT-IBDQ: Social function0.15 (-0.02 to 0.31)
SDT-WPAI: UC Work Productivity Loss Score-0.14 (-0.36 to 0.09)
SDT-WPAI: UC Absenteeism Score0.03 (-0.17 to 0.22)
SDT-WPAI: UC Presenteeism Score-0.17 (-0.38 to -0.06)
SDT-WPAI: UC Activity Impairment Score-0.17 (-0.32 to -0.00)
SDT-Generalize Anxiety Disorder-7 Score0.03 (-0.14 to 0.19)
SDT- APU for BU0.07 (-0.09 to 0.23)
APU-IBDQ: IBDQ Total score-0.290 (-0.436 to -0.126)
APU-IBDQ: Bowel symptoms-0.240 (-0.392 to -0.073)
APU-IBDQ: Systemic symptoms-0.160 (-0.319 to 0.010)
APU-IBDQ: Emotional function-0.258 (-0.409 to -0.093)
APU-IBDQ: Social function-0.321 (-0.464 to -0.160)
APU-WPAI: Work Productivity Loss Score0.040 (-0.194 to 0.269)
APU-WPAI: Absenteeism Score-0.031 (-0.228 to 0.169)
APU-WPAI: Presenteeism Score0.030 (-0.204 to 0.259)
APU-WPAI: Activity Impairment Score0.153 (-0.010 to 0.308)
APU-WPAI: Generalize Anxiety Disorder-7 Score0.139 (-0.025 to 0.294)
UNRS: PGR-S0.672 (0.575 to 0.748)
UNRS: Mayo SF0.478 (0.348 to 0.589)
UNRS: Mayo RB0.368 (0.225 to 0.494)
UNRS: Abdominal Pain NRS0.667 (0.570 to 0.744)
UNRS: Fatigue NRS0.601 (0.491 to 0.691)
UNRS: Nocturnal Stool0.191 (0.036 to 0.335)
BUF: PGR-S0.502 (0.375 to 0.609)
BUF: Mayo SF0.477 (0.346 to 0.587)
BUF: Mayo RB0.351 (0.207 to 0.480)
BUF: Abdominal Pain NRS0.399 (0.258 to 0.521)
BUF: Fatigue NRS0.404 (0.264 to 0.525)
BUF: Nocturnal Stool0.579 (0.464 to 0.672)
SDT: PGR-S-0.44 (-0.55 to -0.30)
SDT: Absolute SF-0.23 (-0.37 to -0.08)
SDT: Mayo SF-0.35 (-0.48 to -0.21)
SDT: Mayo RB-0.22 (-0.37 to -0.07)
SDT: Abdominal Pain NRS-0.39 (-0.52 to -0.25)
SDT: Fatigue NRS-0.30 (-0.43 to -0.15)
SDT: Nocturnal Stool-0.07 (-0.22 to 0.09)
APU: PGR-S0.047 (-0.114 to 0.206)
APU: Mayo SF0.177 (0.018 to 0.327)
APU: Mayo RB0.120 (-0.041 to 0.274)
APU: Abdominal Pain NRS0.168 (0.008 to 0.319)
APU: Fatigue NRS0.154 (-0.007 to 0.306)
APU: Nocturnal Stool0.115 (-0.047 to 0.270)

Adverse events

Collected over Baseline Up to Week 12. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
300 mg Mirikizumab0/172 (0%)5/172 (2.9%)53/172 (30.8%)
Most frequent serious events
Most frequent serious events
Event300 mg Mirikizumab
Any eventBlood and lymphatic system disorders1/172
AnaemiaBlood and lymphatic system disorders1/172
Any eventGastrointestinal disorders1/172
Colitis ulcerativeGastrointestinal disorders1/172
Any eventInfections and infestations1/172
Joint abscessInfections and infestations1/172
Any eventRespiratory, thoracic and mediastinal disorders1/172
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/172
Any eventVascular disorders1/172
Deep vein thrombosisVascular disorders1/172
Most frequent other events
Showing 10 of 36
Most frequent other events
Event300 mg Mirikizumab
Any eventGeneral disorders12/172
Any eventInfections and infestations11/172
Any eventGastrointestinal disorders10/172
Upper respiratory tract infectionInfections and infestations7/172
Any eventMetabolism and nutrition disorders6/172
Any eventNervous system disorders6/172
FatigueGeneral disorders5/172
Any eventBlood and lymphatic system disorders4/172
AnaemiaBlood and lymphatic system disorders4/172
HypercholesterolaemiaMetabolism and nutrition disorders4/172

Baseline characteristics

All enrolled participants.

Age, Continuous
Age, Continuous(years)300 mg Mirikizumab
Mean41.10 ± 14.352
Sex: Female, Male
Sex: Female, Male(Participants)300 mg Mirikizumab
Female71
Male101
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)300 mg Mirikizumab
Hispanic or Latino6
Not Hispanic or Latino151
Unknown or Not Reported15
Race (NIH/OMB)
Race (NIH/OMB)(Participants)300 mg Mirikizumab
American Indian or Alaska Native1
Asian4
Native Hawaiian or Other Pacific Islander0
Black or African American5
White150
More than one race1
Unknown or Not Reported11
Region of Enrollment
Region of Enrollment(Participants)300 mg Mirikizumab
Hungary7
United States33
Czechia18
Poland50
Italy32
United Kingdom6
Slovakia10
France16
08

Study locations

120 sites
  • Dedicated Clinical Research
    Litchfield Park, Arizona 85340, United States
  • Arizona Digestive Health - Sun City
    Sun City, Arizona 85351, United States
  • Om Research, LLC
    Lancaster, California 93534, United States
  • California Medical Research Associates, Inc.
    Northridge, California 91324, United States
  • Clinical Applications Laboratories, Inc.
    San Diego, California 92103, United States
  • Medical Research Center of Connecticut, LLC
    Hamden, Connecticut 06518, United States
  • Central Florida Gastro Research
    Clearwater, Florida 33762, United States
  • Encore Borland-Groover Clinical Research
    Jacksonville, Florida 32256, United States
  • Research Associates of South Florida
    Miami, Florida 33134, United States
  • Advanced Research Associates, LLC
    Miami, Florida 33176, United States
  • GCP Clinical Research, LLC
    Tampa, Florida 33609, United States
  • International Center for Research LLC
    Tampa, Florida 33614, United States
  • Digestive Healthcare of Georgia
    Atlanta, Georgia 30309, United States
  • Atlanta Center for Gastroenterology, P.C.
    Decatur, Georgia 30033, United States
  • Grand Teton Research Group, PLLC
    Idaho Falls, Idaho 83404, United States
  • IU Health University Hospital
    Indianapolis, Indiana 46202, United States
  • Gastroenterology Health Partners
    New Albany, Indiana 47150, United States
  • Cotton-O'Neil Clinical Research Center, Digestive Health
    Topeka, Kansas 66606, United States
  • GI Alliance/ Metairie
    Metairie, Louisiana 70006, United States
  • Delta Research Partners
    Monroe, Louisiana 71201, United States
  • Chevy Chase Clinical Research
    Chevy Chase, Maryland 20815, United States
  • Clinical Research Institute of Michigan, LLC
    Chesterfield, Michigan 48038, United States
  • West Michigan Clinical Research Center
    Wyoming, Michigan 49529, United States
  • NY Scientific
    Brooklyn, New York 11235, United States
  • Digestive Health Partners - Research Department
    Asheville, North Carolina 28801, United States
  • Charlotte Gastroenterolgy & Hepatology
    Charlotte, North Carolina 28207, United States
  • Innovo Research:Wilmington Health
    Wilmington, North Carolina 28401, United States
  • Optimed Research, LTD
    Columbus, Ohio 43235, United States
  • Paramount Medical Research & Consulting, LLC
    Middleburg Heights, Ohio 44130, United States
  • Central Sooner Research
    Norman, Oklahoma 73071, United States
  • University Gastroenterology
    Providence, Rhode Island 02904, United States
  • Gastro One
    Cordova, Tennessee 38018, United States
  • Tri-Cities Gastroenterology
    Kingsport, Tennessee 37663, United States
  • Clinical Trial Network
    Houston, Texas 77074, United States
  • Houston Endoscopy And Research Center, LLC
    Houston, Texas 77079, United States
  • Biopharma Informatic, LLC
    Houston, Texas 77084, United States
  • Citrine Institute for Research and Wellness
    Katy, Texas 77494, United States
  • AngioCardiac Care of Texas, PA
    McAllen, Texas 78503, United States
  • Digestive System Healthcare
    Pasadena, Texas 77505, United States
  • LinQ Research, LLC
    Pearland, Texas 77584, United States
  • Gastroenterology Research of San Antonio
    San Antonio, Texas 78229, United States
  • Southern Star Research Institute, LLC
    San Antonio, Texas 78229, United States
  • Gastroenterology Associates of Texas - Denise Rodriguez
    Sugar Land, Texas 77479, United States
  • Tyler Research Institute, LLC
    Tyler, Texas 75701, United States
  • GI Alliance Research Webster
    Webster, Texas 77598, United States
  • Care Access Research - Ogden
    Ogden, Utah 84403, United States
  • Charlottesville Medical Research
    Charlottesville, Virginia 22911, United States
  • Washington Gastroenterology
    Bellevue, Washington 98004, United States
  • Washington Gastroenterology dba GI Alliance
    Tacoma, Washington 98405, United States
  • Universitair Ziekenhuis Gent - Gastro IBD
    Ghent, 9000, Belgium
  • UZ Leuven - E507 Studies IBD tav Tine Hermans
    Leuven, 3000, Belgium
  • Vojenska nemocnice Brno, Interni oddeleni
    Brno, Czech Republic 63600, Czechia
  • GastroJeka s.r.o
    Klatovy, Czech Republic 33901, Czechia
  • FN Ostrava, Interní Klinika
    Ostrava, Czech Republic 708 52, Czechia
  • Hepato-gastroenterologie HK, s.r.o.
    Hradec Králové, Hradec Králové 50012, Czechia
  • MUDr. Gregar, s.r.o.
    Olomouc, Olomouc Region 779 00, Czechia
  • SurGal clinic s.r.o.
    Brno, 602 00, Czechia
  • PreventaMed, s.r.o.
    Olomouc, 779 00, Czechia
  • Hospices Civils de Lyon - Hôpital Lyon Sud - ARC HGE bâtiment 3I
    Lyon - Pierre Benite, France 69495, France
  • CHU Bordeaux - Hôpital Haut-Lévêque
    Pessac, Gironde 33604, France
  • CHU Rennes - Hôpital Pontchaillou
    Rennes, Ille Et Vilaine 35000, France
  • Centre Hospitalier de Pau
    Pau, Pyrénées-Atlantiques 64046, France
  • Chu Besancon
    Besançon, 25000, France
  • CHU de LILLE - Bureau des ARCs Gastro - HPDD
    Lille, 59037, France
  • Hôpital Saint-Eloi Pôle Digestif ,APEMAD - Recherche clinique
    Montpellier, 34295, France
  • CHU Nantes
    Nantes, 44093, France
  • Clinique Jules Verne
    Nantes, 44300, France
  • Unité de Recherche Clinique (4èmeB)
    Nice, 06-202, France
  • Chu de Reims - Hôpital Robert Debré
    Reims, 51092, France
  • CHU de Saint-Etienne
    Saint-Etienne, 42055, France
  • Chru Nancy Brabois
    Vandœuvre-lès-Nancy, 54511, France
  • Praxis Dr. M. Mross - Gastroenterologie
    Berlin, 10118, Germany
  • DRK Kliniken Berlin Westend, Gastroenterologie, Studienbüro
    Berlin, 14050, Germany
  • Universitätsklinikum Leipzig, Med. Klinik II
    Leipzig, 04 103, Germany
  • Bugat Pal Korhaz
    Gyöngyös, Heves County 3200, Hungary
  • Clinepert kft
    Budapest, 1033, Hungary
  • Semmelweis Egyetem, Belgyógyászati es Hematológiai Klinika
    Budapest, 1088, Hungary
  • Pannónia Magánorvosi Centrum
    Budapest, 1136, Hungary
  • Clinfan Ltd. Gastroenterology Clinic
    Szekszárd, 7100, Hungary
  • Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (Presidio Spedali Civili)
    Brescia, 25123, Italy
  • IRCCS Saverio de Bellis, National Institute of Gastroenterology
    Castellana Grotte, 70013, Italy
  • Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico
    Milan, 20122, Italy
  • Irccs Ospedale San Raffaele, Gastroenterologia/Ibd Unit, Settore G Piano -1
    Milan, 20132, Italy
  • Fondazione Policlinico Agostino Gemelli IRCCS_ CEMAD
    Roma, 00 168, Italy
  • Uoc Gastroenterologia - Policlinico Tor Vergata
    Roma, 00133, Italy
  • IRCCS Istituto Clinico Humanitas- Centro Malattie Infiammatorie Intestinali
    Rozzano, 20089, Italy
  • A.O.Ordine Mauriziano, SC Gastroenterologia, ambulatorio endoscopia digestiva
    Torino, 10128, Italy
  • Solumed Centrum Medyczne
    Poznan, Greater Poland Voivodeship 60-529, Poland
  • MZ Badania Słowik Zymła Sp.j.
    Knurów, Silesian Voivodeship 44 190, Poland
  • Centrum Medyczne Medyk
    Rzeszów, Subcarpathian 35-326, Poland
  • NZOZ Centrum Medyczne KERmed
    Bydgoszcz, 85 231, Poland
  • Vitamed Galaj I Cichomski sp.j.
    Bydgoszcz, 85-079, Poland
  • Centrum Medyczne Plejady
    Krakow, 30 363, Poland
  • KRAKOWSKIE CENTRUM MEDYCZNE Sp. z o.o
    Krakow, 31 501, Poland
  • Topolowa Medicenter Ryszawa & Wspólnicy Sp.j.
    Krakow, 31-506, Poland
  • IP Clinic
    Lodz, 90-752, Poland
  • Med-GASTR SP. Z O.O., SP.K.
    Lodz, 91 034, Poland
  • AmiCare Sp. z o.o. Sp. K.
    Lodz, 91 495, Poland
  • Bonifraterskie Centrum Medyczne sp. z o.o
    Lodz, 93-357, Poland
  • Allmedica Badania Kliniczne Sp. z o.o. Sp. k.
    Nowy Targ, 34-400, Poland

Showing the first 100 of 120 sites across 10 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Danese S, Dignass A, Laharie D, Limdi JK, Kempinski R, Lewis JD, Younes Z, Cohen E, Alaka K, Eastman WJ, Tian T, Redondo I, Rubin DT, Dubinsky M. Mirikizumab is associated with rapid and sustained improvements in novel measures of bowel urgency in moderately-to-severely active ulcerative colitis: 28-week results from the LUCENT-URGE trial. J Crohns Colitis. 2026 May 8;20(5):jjag049. doi: 10.1093/ecco-jcc/jjag049. PubMed 42112567 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Time Frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Aug 2024, 14 months.

Results were first posted in Sep 2025, 1 year 1 month after primary completion.

Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 14 months is below that.

Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2023
First posted
Mar 14, 2023
StartActual
May 17, 2023
Primary completionActual
Aug 9, 2024
CompletionActual
Apr 27, 2026
Results first posted
Sep 30, 2025
Last update
Jun 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05767021
Responsible party
Sponsor
First posted
Mar 14, 2023
Start date
May 17, 2023
Primary completion
Aug 9, 2024
Completion
Apr 27, 2026
Results posted
Sep 30, 2025
Last update
Jun 10, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mirikizumab

Start the discussion